latest news releases from the newsroom
Sagient Research Systems
Sagient Research Reports Significant Decline in FDA Drug Approval Rate
SAN DIEGO, Jan. 9, 2008 (PRIME NEWSWIRE) -- Sagient Research Systems, a leading publisher of independent research for the financial services and institutional investment communities, today issued a research report documenting a significant decline in FDA Drug Approvals in 2007. According to its biotechnology research service BioMedTracker, the FDA's drug approval rate declined 13% in 2007 while the rate of approvable letters issued increased by 40% and non-approvable letters increased by 22%. An approvable letter is issued when additional data is required before the FDA will approve a new drug. It is viewed as a negative event since it requires a delay in the approval process. According to Sagient's volatility event tracking service, CatalystTracker, the average absolute stock price change resulting from an approvable letter issuance dropped to 12.89% in 2007 from 21.42% in 2006.
Christopher & Banks Corporation
Christopher & Banks Corporation Announces Participation in the 10th Annual ICR XChange Conference
MINNEAPOLIS, Jan 09, 2008 -- Christopher & Banks Corporation (NYSE:CBK) today announced that the Company will be presenting at the 10th Annual ICR XChange Conference held at the St. Regis Monarch Beach Resort & Spa in Dana Point, California on Wednesday, January 16, 2008 at 1:00 pm Pacific Standard Time/ 4:00 pm Eastern Standard Time. Lorna Nagler, President and Chief Executive Officer; Monica Dahl, Chief Operating Officer; and Andrew Moller, Chief Financial Officer will host the presentation.